--- title: "Morning Trend | CANSINOBIO continues to decline, when will short-term buying return?" type: "News" locale: "en" url: "https://longbridge.com/en/news/274282399.md" description: "CanSinoBIO (6185.HK) closed lower again on January 30, with occasional tentative buying during the day, but overall fluctuating around the 35 yuan level, lacking the momentum for a sustained rise. The pharmaceutical and innovative drug sectors have recently seen significant adjustments, affected by multiple regulatory pressures and capital withdrawals. CanSino itself has not had any major business updates recently, leading to a cautious and risk-averse market sentiment. Some institutions are attempting to buy at lower prices, but they struggle against overall short-selling pressure, resulting in low trading volumes. Only during short-term overselling do we see small buying orders entering, triggering panic selling with slight volume increases. Sector rebound and intraday capital movements are the only possibilities for future rebounds. From a technical perspective, MACD is weakening, and the K-line is inconsistent throughout the day, with insufficient market sentiment in the main board sector. If it falls below 34.88 yuan in the short term, it may further exacerbate the short-selling advantage. Operational advice: closely monitor intraday movements and sector rebound signals, and control positions until there is a clear return of capital. The overall strategy focuses on right-side following and defensive observation, with timely tracking of medical insurance and policy margins to seize short-term opportunities" datetime: "2026-02-02T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274282399.md) - [en](https://longbridge.com/en/news/274282399.md) - [zh-HK](https://longbridge.com/zh-HK/news/274282399.md) --- # Morning Trend | CANSINOBIO continues to decline, when will short-term buying return? CanSinoBIO (6185.HK) closed lower again on January 30, with occasional tentative buying during the day, but overall fluctuating around the 35 yuan level, lacking the momentum for a sustained rise. The pharmaceutical and innovative drug sectors have recently seen significant adjustments, affected by multiple regulatory pressures and capital withdrawals. CanSino itself has had no major business updates recently, leading to a cautious market sentiment and heightened risk aversion. Some institutions are attempting to buy at lower prices, but it is difficult to counter the overall short selling pressure, resulting in sluggish trading volume. Only during short-term overselling have there been small buying orders that have entered, triggering panic-induced slight volume increases. Sector rebound and intraday capital movements are the only possibilities for future rebounds. From a technical perspective, MACD is weakening, and the K-line is inconsistent throughout the day, with insufficient market sentiment in the main board sector. If it falls below 34.88 yuan in the short term, it may further exacerbate the short selling advantage. Operational advice: closely monitor intraday movements and sector rebound signals, and control positions until there is a clear return of capital. The overall strategy should focus on right-side following and defensive observation, while tracking medical insurance and policy margins to seize short-term opportunities ### Related Stocks - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159987.CN](https://longbridge.com/en/quote/159987.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [06185.HK](https://longbridge.com/en/quote/06185.HK.md) - [688185.CN](https://longbridge.com/en/quote/688185.CN.md) ## Related News & Research - [SSY Group wins China NMPA approval for emedastine difumarate eye drops 0.05%](https://longbridge.com/en/news/287187916.md) - [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md) - [Shanghai Henlius wins Australia clearance to start Phase 1 HLX3902 cancer trial](https://longbridge.com/en/news/287190785.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)